Effects of Local Insulin on Wound Angiogenesis

Status Active, not recruiting

Clinical Trial Summary

Randomized, split plot, double-blind, placebo controlled trial. Half of the wounds surface was applied daily with insulin and the other half with saline solution as placebo. Biopsy specimens of the two sides were obtained on days 0 and 14. Number of blood vessels will be evaluated as main outcome.

Clinical Trial Description

Randomized, split plot, double-blind, placebo controlled trial. Non-diabetic patients with full-thickness wounds will be treated in the following manner: in half of the surface insulin will be applied in a daily basis, on the other half, saline solution will be used as placebo. Biopsy specimens of both sides will be obtained on days 0 and 14. Number of blood vessels will be evaluated as main outcome. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment

Related Conditions & MeSH terms

Angiogenesis

Clinical Trial Details

NCT number	NCT02396888
Study type	Interventional
Source	Hospital Central "Dr. Ignacio Morones Prieto"
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	October 2014
Completion date	May 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT06106932` - GnRH-a on Angiogenesis of Endometriosis	N/A
Completed	`NCT04974983` - Impact of Bevacizumab on Symptom Burden and Neurological Deficits in Patients With Recurrent Glioblastoma
Recruiting	`NCT04566952` - Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer	Phase 2
Recruiting	`NCT04145505` - Micrometastases and Angiogenesis in Colon Cancer. Prognostic Value of VEGF.
Completed	`NCT03705247` - The Role of Bleeding at Implant Placement
Recruiting	`NCT04556071` - Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer	Phase 2
Completed	`NCT04609332` - Endothelial Damage and Angiogenesis Biomarkers During COVID-19
Completed	`NCT03162588` - Multiple Burrhole Therapy With Erythropoietin for Unstable Moyamoya	Phase 1/Phase 2
Recruiting	`NCT04772001` - Concurrent Radiochemotherapy Plus Anlotinib for Locally Advanced Cervical Cancer	N/A
Not yet recruiting	`NCT04807166` - Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer	Phase 2
Completed	`NCT04310280` - Effects of Local Insulin on Varicose Ulcers for Wound Healing	Phase 3
Completed	`NCT04670107` - The Combination of Anlotinib and Immune Checkpoint Inhibitors for Advanced NSCLC Patients With Muti-line Therapy	Phase 1/Phase 2
Completed	`NCT00727948` - The Effect of Aspirin on Angiogenesis Proteins in Women on Tamoxifen Therapy	Early Phase 1
Completed	`NCT02603406` - Neovascularization Induced by Mechanical Barrier disrUption and Systemic Erythropoietin in Patients With Cerebral Perfusion Deficits	Phase 2
Recruiting	`NCT03991871` - HARapan kiTa ECP (External Counter Pulsation) Study HARTEC Study	N/A
Completed	`NCT00744536` - Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS	Phase 2
Completed	`NCT00728598` - Fractalkine, a CX3C Chemokine, Act as a Mediator of Ocular Angiogenesis	N/A
Active, not recruiting	`NCT04851054` - Postoperative VEGF and Recurrence After Colon Cancer Surgery
Not yet recruiting	`NCT02865304` - The Efficacy and Safety of Endostar Combined With Taxane-based Regimens for HER-2-negative MBC Patients	Phase 3
Not yet recruiting	`NCT05595889` - Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer	Phase 2